The Rise of Carbapenem Resistant Organisms

Slides:



Advertisements
Similar presentations
Game plan Lecture Antibiotics Antibiotic resistance Gene transfer Transformation Transduction Conjugation Lab Lab Exam Pre-lab Transformation.
Advertisements

1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis :
Development of Healthcare- Associated Infections: Role of the Built Environment James P. Steinberg, MD Division of Infectious Diseases Emory University.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
1 Benoît GUERY Infectious Diseases CHRU Lille Antibiotic strategies How to treat Multi-drug-resistant Pseudomonas.
Antibiotic treatment choices for SBP Treviso 8 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.
Fred C. Tenover, Ph.D., D(ABMM) Vice President, Scientific Affairs
Antibiotic overuse and misuse in long term care Shira Doron, MD Assistant Professor of Medicine Division of Geographic Medicine and Infectious Diseases.
Factors Leading to the Spread of Vancomycin-Resistant Enterococci in US Hospitals Factors Antimicrobial pressure Environmental contamination and survival.
Shira Doron, MD Assistant Professor of Medicine
Antibiotics Tamar Barlam Infectious Disease Director, Antimicrobial Stewardship.
National and International Spread of Antimicrobial Resistance: Clones and Genes Professor Alan Johnson, Health Protection Services - HPA.
Inappropriate empirical antimicrobial Tx for coagulase-negative staphylococcal (CoNS) bacteraemia: impact on survival Single-centre retrospective cohort.
© Aurora Health Care, Inc. Carbapenem Resistant Enterobacteriaceae The Alphabet Soup of Infection Prevention Aurora Health Care System Infection Prevention.
Moving forward together infection prevention and control and AMR Rose Gallagher Nurse Advisor Infection Prevention and Control Royal College of Nursing.
Division of Public Health CRE Surveillance and Prevention of Transmission in Healthcare Settings Gwen Borlaug, CIC, MPH Coordinator, Healthcare-Associated.
What’s happening now ? Epidemiology of (carbapenem) resistance Neil Woodford HPA – AMRHAI - Colindale.
CARBAPENEM RESISTANT ENTEROBACTERIACEAE: RISK FACTORS AND ROLE OF EXTENDED CARE FACILITIES A. Makarem, MD; P. Alvarez, MD; T. Chou, MPH, CIC; M. Kulkarni,
Carbapenemase- Producing Carbapenem-Resistant Enterobacteriaceae Nicole Hearon, HAI Epidemiologist Surveillance and Investigation Division Indiana State.
European Centre for Disease Prevention and Control
Carbapenemases in practice - lessons learnt from spread in our patch, prophylaxis and first/second line treatments Dr Andrew Dodgson Consultant Microbiologist.
Development of a Real-Time PCR (RT-PCR) Assay for Carbapenemase Producing Bacteria including Enterobacteriaceae B. Mather, P. L. White, M. Wootton, R.
Le infezioni batteriche nel paziente oncoematologico Corrado Girmenia Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy Ematologia.
The role of PHE’s AMRHAI Reference Unit Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit © Crown.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Part II High Priority Resistant Organisms. Healthcare Associated Infections NHSN Staphylococcus aureus (16%) 2.Enterococcus spp (14%) 3.Escherichia.
Acinetobacter Before we begin the investigation, we must prepare for field work. The preparation requires that we learn about the organism involved in.
1 Infectious Diseases in the Nursing Home Setting: Challenges and Opportunities for Clinical Investigation 감염내과 R2 김대호 / Prof. 이미숙 Manisha Juthani-Mehta.
The Growing Threat of Antibiotic Resistance in Post-Acute Care
Pr Jean-Ralph Zahar Infection Control Unit
Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae
Carbapenem Resistant Enterobacteriaceae:
Kelley Garner, MPH MLS(ASCP)CM
8th Annual Infection Prevention Conference 23rd June 2011, Harrogate
Figure 1. Rate of antimicrobial resistance in S. pneumoniae
Alison Holmes, Jonathan Otter
Universidad Militar Nueva Granada, School of Medicine
Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.
carbapenemase-positive Enterobacteriaceae
Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London
Promiscuous plasmids? Scaling infection control implications of horizontal spread of carbapenemase genes between species Siddharth Mookerjee, Frances Davies,
Main modes of transmission CPE
Risk factors for carbapenem-resistant Enterobacteriaceae (CRE) carriage at the time of hospital admission Siddharth Mookerjee,1 Eleonora Dyakova,1 Frances.
Carbapenem-resistant Gram-negative bacteria
Antimicrobial Resistance: from Global to Local
Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources  N. Singh,
Neonatal sepsis in Kilifi
CPE: coming to a hospital near you!
Inside COMBACTE network: global information for a global problem.
Promoting a Public Health Approach to Detecting and Containing Novel and Emergent Antibiotic Resistant Organisms Maroya Walters, PhD, ScM Division of Healthcare.
Clarifying CRE Reporting in NHSN
P. Nordmann, L. Poirel  Clinical Microbiology and Infection 
Antibiotic Resistance
Emerging Issues in Gram-Negative Bacterial Resistance
R. Cantón, M. Akóva, Y. Carmeli, C. G. Giske, Y. Glupczynski, M
The need for new antibiotics
G. Höffken  Clinical Microbiology and Infection 
TRAINING PRESENTATION
Jennifer Henderson1,2, Holly Ciesielczuk1, Shona Nelson2 & Mark Wilks1
Combating the spread of carbapenemases in Enterobacteriaceae: a battle that infection prevention should not lose  P. Savard, T.M. Perl  Clinical Microbiology.
W. -L. Yu, M. -F. Lee, H. -J. Tang, M. -C. Chang, J
G.M. Rossolini, E. Mantengoli  Clinical Microbiology and Infection 
Epidemiological characterization and distribution of carbapenem-resistant Acinetobacter baumannii clinical isolates in Italy  M.L. Mezzatesta, M.M. D'Andrea,
Home Care and Assisted Living Program
Health Protection Surveillance Centre
Carbapenem-Resistant Enterobacteriaceae in the community
Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London
Fighting MDR G-Negative Infections
Belinda Ostrowsky, MD, MPH Field Medical Officer, NY
Outcomes of infections caused by carbapenemase-producing Klebsiella pneumoniae, according to treatment regimen. Outcomes of infections caused by carbapenemase-producing.
Presentation transcript:

The Rise of Carbapenem Resistant Organisms RUSI/STFC workshop on Antimicrobial Resistance 6th February 2013 Professor Mike Sharland Professor of Paediatric Infectious Diseases St George’s, University of London Chair of the DH advisory committee on Antimicrobial Resistance and Healthcare Associated Infections (ARHAI)

Carbapenem Resistant Organisms (CRO’s) Extremely Resistant Gram Negative Bacteria Complex names – KPC, NDM, VIM, OXA – enzymes and bacteria Rapid global Spread Resistant to last decent antibiotic class – carbapenems (meropenem) With inadequate treatment can become pan-resistant

CRO – Serious Adverse Outcomes Mortality 20-40% - associated with: Extended Hospital Stay Esp ICU Exposure to Invasive Devices E.g. Ventilators, Central Venous Catheters Comorbidities assoc with Advanced Age E.g. immunosupression, cardiac disease, chronic airway disease – also premature

Worldwide Distribution of Klebsiella pneumoniae carbapenemase producers Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

Spread of NDM-Mediated Carbapenem Resistance Johnson and Woodford J Med Micro 2013; doi: 10.1099/jmm.0.052555-0

Klebsiella pneumoniae: percentage of invasive isolates with resistance to carbapenems. 2010 2011

KPC-producing K. pneumoniae - Italian experience early 2011 late 2012 late 2008 The first reported cases of KPC-Kp (ST258) ST258, ST512 (CC258) ST512 ST258 Fontana et al – BMC Res Notes 2010 Marchese et al – J Chemother 2010 Ambretti et al – New Microb 2010 Gaibani et al – Eurosurv 2011 Mezzatesta et al – CMI 2011 Agodi et al – JCM 2011 Richter et al – JCM 2011 Di Carlo et al – BMC Gastroenterol 2011 Rossolini GM – unpublished ST101 ST15 ST147-like AMCLI – CoSA CRE network Frasson et al – JCM 2012 ARISS-CoSA study – unpublished Giani et al – JCM 2009 Rossolini GM – unpublished

Carbapenen-resistant K. pneumoniae AMCLI-CoSA – Italian National CRE Surveillance 2011

AMCLI-CoSA – Italian National CRE Surveillance 2011

Israel’s KPC Outbreak and Intensive IPC Intervention

Antimicrobial Resistance spread into and within the UK CRO colonized residents or visitors Hospital treatment or travel overseas Non-human reservoirs: foodstuffs (domestic or imported) Medical Tourism Elective & cosmetic Non-human reservoirs: animals and environment Military and civilian casualties from conflict zones Community Carriage? Inter-hospital transfers (UK)